0000000000320988

AUTHOR

Wolf-karsten Hofmann

showing 3 related works from this author

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

2017

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drugEuropean journal of haematology
researchProduct

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

2013

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.

OncologyAdultMalemedicine.medical_specialtyPediatricsCancer ResearchScoring systemAllogeneic transplantationSurvivalAdolescenturologic and male genital diseasesRisk AssessmentIPSS; IPSS-R; MDS; Prognosis; Survival; WPSS; Hematology; Oncology; Cancer ResearchRisk categoryYoung AdultRisk FactorsInternal medicinemedicineMDSHumansIn patientAgedAged 80 and overIPSS-Rbusiness.industryIPSSInduction chemotherapyReproducibility of ResultsHematologyMiddle AgedPrognosisSurvival AnalysisMulticenter studyOncologyInternational Prognostic Scoring SystemLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseMultivariate AnalysisDisease ProgressionWPSSFemalebusinessLeukemia research
researchProduct

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced F…

2018

Abstract Introduction: Advanced follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. About 20% of patients have early progression of disease (POD) and short overall survival (OS). We have previously shown that integration of lymphoma-specific gene mutations and clinical factors improves pretreatment risk stratification (Pastore, 2015) and prediction of early POD (i.e., within 24 months, POD24; Jurinovic, 2016). Recently, we have shown that high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) is an effective treatment option for eligible patients with high-risk disease as defined by POD24 (Jurinovic, 2018). Here, we aimed to explore wheth…

medicine.medical_specialtyIntention-to-treat analysisbusiness.industryImmunologyFollicular lymphomaCell BiologyHematologyGene mutationmedicine.diseaseBiochemistryTransplantationAutologous stem-cell transplantationInternational Prognostic IndexInternal medicineCohortmedicineIn patientbusinessBlood
researchProduct